Figure 5.

SRGN enhances HDAC2 expression to maintain SC traits in BC cells. (A) Efficiency of HDAC2 knockdown in chemoresistant BC cells was validated by Western blotting. (B) IC50 values of drugs in cell lines with HDAC2 knockdown were calculated by the MTS assays. Student's t-test, mean ± s.d. (n=3), _** p < 0.01, _*** p < 0.001, _**** p < 0.0001. (C) The CD44^high/CD24^low subpopulation was examined by flow cytometry and the mammosphere-forming ability was assessed in cell lines with HDAC2 knockdown. Scale bar, 100 μm. Student's t-test, mean ± s. d. (n=3), _*** p < 0.001. (D) HDAC2 protein expression was detected by Western blotting. (E) IC50 values of drugs in MCF-7 cells with HDAC2 knockdown and SRGN overexpression were calculated by the MTS assay. Student's t-test, mean ± s.d. (n=3), _** p < 0.01, _*** p < 0.001. (F) CD44^high/CD24^low cell population was examined by flow cytometry and the mammosphere-forming ability was assessed in MCF-7 cells with HDAC2 knockdown and SRGN overexpression. Scale bar, 100 μm. Student's t-test, mean ± s.d. (n=3), _** p < 0.001.